Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

Richard S. Finn, MD
Published: Tuesday, Oct 11, 2016



Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

PALOMA-2 is a randomized double-blind phase III trial designed to confirm the results of PALOMA-1, which found that the addition of palbociclib (Ibrance) to letrozole (Femara) significantly improved progression-free survival compared with letrozole alone.

Preclinical data has suggested that patients with ER+ breast cancer would specifically benefit from a CDK 4/6 inhibitor such as palbociclib, Finn explains. The current data confirm the agent's consistent efficacy in several different subgroups of biomarkers.


Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

PALOMA-2 is a randomized double-blind phase III trial designed to confirm the results of PALOMA-1, which found that the addition of palbociclib (Ibrance) to letrozole (Femara) significantly improved progression-free survival compared with letrozole alone.

Preclinical data has suggested that patients with ER+ breast cancer would specifically benefit from a CDK 4/6 inhibitor such as palbociclib, Finn explains. The current data confirm the agent's consistent efficacy in several different subgroups of biomarkers.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x